Quick Take
BridgeBio (BBIO) has filed to raise gross proceeds of up to $225 million from a U.S. IPO, according to an S-1/A registration statement.
The group is developing therapeutics for Mendelian diseases, or diseases arising from defects in a single gene as well as cancers with clear genetic drivers.
BBIO is pursuing a very broad and diverse set of treatment programs and is asking for a high IPO valuation.
Company & Technology
Palo Alto, California-based BridgeBio was founded in 2015 to develop therapeutics for patients suffering from Mendelian diseases or cancers